Acrivon Therapeutics, Inc. Common Stock
ACRV · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.28 | -0.02 | -0.10 | -0.10 |
| FCF Yield | -3.36% | -40.44% | -12.78% | -4.10% |
| EV / EBITDA | -25.12 | -1.29 | -7.58 | -16.43 |
| Quality | ||||
| ROIC | -49.44% | -53.06% | -18.84% | -15.79% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.82 | 0.71 | 0.97 | 0.86 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | -100.00% |
| Free Cash Flow Growth | -55.79% | -36.07% | -127.03% | -404.61% |
| Safety | ||||
| Net Debt / EBITDA | 0.45 | 0.52 | 0.82 | 6.10 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -275.02 | -3,437.54 | -301.33 | -422.91 |